Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии, психотерапии и психосоматической патологии РУДН
Список исп. литературыСкрыть список 1. Аведисова А.С., Вериго Н.Н. Шизофрения и когнитивный дефицит. Психиатр. и психофармакотер. 2001; 6: 5. 2. Белоусов Ю.Б., Белоусов Д.Ю., Омельяновский В.В. и др. Фармакоэкономическая эффективность атипичных антипсихотиков у больных шизофренией. Психиатр. и психофармакотер. 2007; 4. 3. Головин С.А. Опыт применения оланзапина в процессе медико-социальной реабилитации больных в наркологической клинике. Психиатр. и психофармакотер. 2003; 4: 163–7. 4. Григорьева Е.А., Рицков А.С. Применение оланзапина при лечении депрессивно-бредовых расстройств. Психиатр. и психофармакотер. 2001; 3 (6): 204–7. 5. Григорьева Е.А., Рицков А.С., Ипатов М.Ю. Сравнительное клиническое и катамнестическое изучение действия оланзапина и сочетания амитриптилина с галоперидолом при терапии депрессивно-бредовых расстройств. Психиатр. и психофармакотер. 2004; 3. 6. Зеленина Е.В. Оланзапин у больных шизофренией с признаками терапевтической резистентности. Психиатр. и психофармакотер. 2002; 4: 145–7. 7. Ипатов М.Ю. Оланзапин: сравнение с рисперидоном (обзор исследований). Психиатр. и психофармакотер. 2004; 4: 106–10. 8. Кинкулькина М.А. Оланзапин в сравнении с галоперидолом при лечении острых психотических состояний у эндогенных больных. Психиатр. и психофармакотер. 2003; 6: 257–9. 9. Морозова М.А. Спектр клинической активности атипичного антипсихотика оланзапина. Психиатр. и психофармакотер. 2000; 2 (5): 144–6. 10. Морозова М.А. Резистентность к антипсихотикам и возможности оланзапина в рефрактерных к терапии случаях шизофрении. Психиатр. и психофармакотер. 2002; 3: 113–8. 11. Морозова М.А., Жаркова Н.Б., Бениашвили А.Г. Опыт применения атипичного нейролептика оланзапина в остром периоде шизофрении. Неврол. и психиатр. 2000; 100 (4): 37–43. 12. Мосолов С.Н., Калинин В.В., Еремин А.В. Сравнительная эффективность и переносимость нового поколения антипсихотических средств при лечении обострений шизофрении (метаанализ оригинальных исследований оланзапина, рисперидона, кветиапина, клозапина и галоперидола). В сб.: Новые достижения в терапии психических заболеваний. М., 2002; с. 82–94. 13. Раевский К.С. Современные нейролептики: взаимодействие с системами нейротрансмиттеров мозга. Психиатр. и психофармакотер. 2000; 5: 132–4. 14. Четвертных И.И., Мосолов С.Н., Калинин В.В., Сулимов Г.Ю. Сравнительная эффективность и переносимость длительного применения рисперидона, кветиапина и оланзапина в сравнении с галоперидолом у больных с впервые выявленной шизофренией (открытое рандомизированное исследование). Психиатр. и психофармакотер. 2005; 4. 15. Alptekin K, Hafez J, Brook S et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 2009; 24 (5): 229–38. 16. Alvarez E, Ciudad A, Olivares JM et al. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 2006; 26 (3): 238–49. 17. Baldacchino AM, Stubbs JH, Mountjoy CQ. Olanzapine. Hosp Med 1998; 59 (9): 737. 18. Beasley CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol. Neuropsychopharmacol 1996; 14: 111–23. 19. Beasley CM, Tollefson GD, Sanger T et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol 1996; 14: 105–18. 20. Breier A, Roychowdhury S, Sethuraman G et al. Сравнение оланзапина с другими атипичными антипсихотиками в профилактике рецидивов у пациентов с шизофренией. Психиатр. и психофармакотер. 2006; 1. 21. Breier A, Berg PH, Thakore JH et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005; 162 (10): 1879–87. 22. Brune M, Abdel-Hamid M, Lehmkamper C, Sonntag C. Mental state attribution, neurocognitive functioning, and psychopathology. What predicts poor social competence in schizophrenia best? Schizophrenia Research 2007; 92 (1–2): 151–9. 23. Buckley PF. Olanzapine: a critical review of recent literature. Expert Opin Pharmacother 2005; 6 (12): 2077–89. 24. Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996; 14 (2): 87–96. 25. Callaghan JT, Bergstrom RF, Ptak LR et al. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37 (3): 177–93. 26. Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 2005; 25: 388–91. 27. Conley R, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiat 2001; 158 (5): 765–74. 28. Dossenbach M, O’Halloran RA, Boland J. Change in clinical status and side effects of patients treated with either olanzapine or risperidone: 6 month results from the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) observational study. International Congress on Schizophrenia Research 2003. Colorado Springs, CO. 29. Dossenbach M, Pecenak J, Szulc A et al. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. J Clin Psychiat 2008; 69 (12): 1901–15. 30. Dursun SM, Gardner DM, Bird DC, Flinn J. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiat 1999; 44 (7): 701–4. 31. Crespo-Facorro B, Pérez-Iglesias R, Mata I et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. J Psychopharmacol 2011; 25 (6): 744–54. 32. Gomez JC, Sacristan JA, Carrasco PR. Safety and effectiveness of olanzapine vs other antipsychotic drugs in the treatment of outpatients with schizophrenia. Eur Neuropsychopharmacol 1999; 9 (Suppl. 5): s290. 33. Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull 2005; 31: 910–21. 34. Gureje O, Miles W, Keks N et al. Olanzapine versus risperidone in the management of schizophrenia: A randomized double-blind trial in Australia and New Zealand. Schizophr Res 2002; 61: 303–14. 35. Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161 (6): 985–95. 36. Kinon BJ, Hill AL, Liu-Seifert H. Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Biol Psychiatry 2003; 53: s25. 37. Kinon BJ, Lipkovich I, Edwards SB et al. A 24-week, randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006; 26: 157–62. 38. Kinon BJ, Liu-Seifert H, Adams DH, Citrome L. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol 2006; 26 (6): 632–7. 39. Kinon BJ, Volavka J, Stauffer V et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28 (4): 392–400. 40. Kjelby E, Jørgensen HA, Kroken RA et al. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiat 2011; 11 (1): 145. 41. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophrenia Research 2005; 74 (1): 15–26. 42. Kurtz MM, Moberg JP, Ragland JD et al. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 2005; 31: 167–74. 43. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of anti-psychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23. 44. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005; 3: 21. 45. Moore NA, Tye NC, Axton MS et al. The behavioral pharmacology of olanzapine, a novel «atypical» antipsychotic agent. J Pharmacol Exp Ther 1992; 262 (2): 545–51. 46. Olajossy-Hilkesberger L, Godlewska B, Schosser-Haupt A et al. Polymorphisms of the 5-HT2A-receptor gene and clinical response to olanzapine in paranoid schizophrenia. Neuropsychobiol 2011; 64 (4): 202–10. 47. Pelagotti F, Santarlasci B, Vacca F et al. Dropout rates with olanzapine or risperidone: a multi-centre observational study. Eur J Clin Pharmacol 2004; 59: 905–9. 48. Pilowsky LS, Busatto GF, Taylor M et al. Dopamine D2-receptor occupancy in vivo by the novel atypical antipsychotic olanzapine-a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacol 1996; 124: 148–53. 49. Prabhakar M, Haynes WG, Coryell WH et al. Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. Pharmacother 2011; 31 (8): 806–12. 50. Purdon SE, Jones BD, Stipp E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000; 57 (3): 249–58. 51. Santarlasci B, Messori A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother 2003; 37: 556–63. 52. Tolleson G, Beasley C et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–65. 53. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001; 49 (1): 52–63. 54. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18. 55. Tran PV, Tollefson GD, Sanger TM et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. Br J Psychiatry 1999; 174: 15–22. 56. Volavka J, Czobor P, Sheitman B et al. Clozapine, olanzapine, risperidone and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159 (2): 255–62. 57. Wagner M, Quednow BB, Westheide J et al. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacol 2005; 30 (2): 381–90.